NEW YORK — Epigenetic biomarker developer Foxo Technologies said on Wednesday that it has raised $10 million in private financing.
The investment round was led by Bespoke Growth Partners and brings Foxo's total amount of funding raised to date to $40 million, the Minneapolis-based company said.
Foxo said it will use the money to continue developing its bioinformatics and DNA microarray technologies for identifying epigenetic biomarkers of health and aging. The company currently offers biomarker discovery using Illumina Infinium Human and Infinium Mouse Methylation Arrays for DNA methylation testing and its MethylSuite software for epigenetic data analysis. The company is also preparing to launch a life insurance service called Foxo Life.
"The maturation of DNA sequencing technology platforms coupled with [artificial intelligence] and bioinformatic tools is creating a new era in the science of health and wellness," Foxo Founder and CEO Jon Sabes said in a statement. "We are harnessing these technologies to create proprietary, hyper-personalized epigenetic biomarkers of health and wellness that work synergistically with life insurance."